David Krempa Sells 42,797 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider owned 25,249 shares in the company, valued at $843,064.11. The trade was a 62.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $31.86 on Friday. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $872.65 million, a price-to-earnings ratio of -455.08 and a beta of 0.82. The firm’s fifty day simple moving average is $26.85 and its 200 day simple moving average is $20.14. Eton Pharmaceuticals, Inc. has a twelve month low of $13.09 and a twelve month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The business had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, equities research analysts expect that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ETON has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. B. Riley Financial lifted their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Finally, Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Eton Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $41.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. increased its stake in Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after buying an additional 7,930 shares during the period. EcoR1 Capital LLC increased its position in shares of Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after purchasing an additional 31,942 shares during the last quarter. State Street Corp increased its position in shares of Eton Pharmaceuticals by 14.5% in the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after purchasing an additional 63,480 shares during the last quarter. Finally, Cannell Capital LLC increased its position in shares of Eton Pharmaceuticals by 17.3% in the 3rd quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock worth $9,896,000 after purchasing an additional 67,230 shares during the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.